Pharming Group N.V. (PHAR) Key Metrics
PHAR valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $662.5M
- Enterprise value
- $737.5M
- P/E (TTM)
- 72.0 10-yr median 58.5
- Forward P/E
- 212.8
- PEG ratio
- —
- Price / sales
- 1.8 10-yr median 3.6
- Price / book
- 3.0 10-yr median 4.1
- EV / EBITDA
- 19.0 10-yr median 30.5
- Dividend yield
- —
- Beta
- 0.07
PHAR key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPHAR valuation Price multiples at each fiscal year-end price.
PHAR returns How much profit the business earns on the capital it uses.
PHAR per-share figures Results divided by the shares outstanding at year-end.
PHAR financial health Debt, liquidity and how easily interest is covered.
PHAR efficiency & capital use Working capital cycle and where the cash goes.
PHAR valuation history
PHAR returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PHAR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PHAR price vs earnings per share
PHAR key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.26B | $693.7M | $751.0M | $929.7M | $783.5M | $1.23B | — | — | — | — |
| Enterprise value | $1.20B | $636.1M | $709.1M | $889.0M | $749.3M | $1.20B | — | — | — | — |
| P/E ratio | 442.0 | — | — | 68.0 | 49.0 | 32.6 | — | — | — | — |
| Price / sales | 3.4 | 2.3 | 3.1 | 4.5 | 3.9 | 5.8 | — | — | — | — |
| Price / book | 4.5 | 3.0 | 3.4 | 4.5 | 3.6 | 8.2 | — | — | — | — |
| Price / free cash flow | 23.4 | — | — | 45.4 | 37.1 | 18.0 | — | — | — | — |
| Price / operating cash flow | 23.0 | — | — | 41.4 | 20.7 | 14.7 | — | — | — | — |
| EV / sales | 3.2 | 2.1 | 2.9 | 4.3 | 3.8 | 5.6 | — | — | — | — |
| EV / EBITDA | 34.4 | 39.0 | 71.8 | 26.5 | 15.4 | 20.5 | — | — | — | — |
| EV / free cash flow | 22.2 | — | — | 43.4 | 35.5 | 17.5 | — | — | — | — |
| Earnings yield | 0.2% | −1.7% | −1.4% | 1.5% | 2.0% | 3.1% | — | — | — | — |
| Free cash flow yield | 4.3% | −0.4% | −2.5% | 2.2% | 2.7% | 5.6% | — | — | — | — |
| Dividend yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Share price at fiscal year-end | $17.67 | $10.06 | $11.43 | $11.03 | $8.94 | $15.20 | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $5.27 | $4.31 | $3.73 | $2.44 | $2.27 | $2.62 | $2.25 | $1.89 | $1.72 | $0.32 |
| Earnings per share | $0.04 | −$0.17 | −$0.16 | $0.16 | $0.18 | $0.47 | $0.48 | $0.35 | −$1.46 | −$0.36 |
| Operating cash flow per share | $0.77 | −$0.03 | −$0.26 | $0.27 | $0.43 | $1.03 | $0.88 | $0.57 | $0.73 | −$0.20 |
| Free cash flow per share | $0.76 | −$0.04 | −$0.29 | $0.24 | $0.24 | $0.84 | $0.58 | $0.51 | $0.62 | −$0.23 |
| Cash per share | $2.52 | $2.52 | $3.25 | $2.46 | $2.48 | $2.07 | $0.88 | $0.98 | $1.13 | $0.65 |
| Book value per share | $3.88 | $3.32 | $3.33 | $2.43 | $2.50 | $1.85 | $1.39 | $0.76 | $0.26 | $0.53 |
| Tangible book value per share | $0.13 | $2.40 | $2.25 | $1.54 | $1.41 | $0.96 | $0.45 | $0.02 | −$0.83 | −$0.62 |
| Dividends per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | $0.00 | — |
| Capex per share | $0.01 | $0.01 | $0.02 | $0.02 | $0.19 | $0.19 | $0.30 | $0.05 | $0.12 | $0.03 |
| Debt per share | $1.62 | $1.69 | $2.61 | $1.98 | $2.09 | $1.64 | $0.69 | $1.02 | $1.31 | $1.30 |
| Shares outstanding | 71.3M | 68.9M | 65.7M | 84.3M | 87.6M | 81.0M | 84.2M | 81.7M | 62.6M | 51.9M |
| Change in shares outstanding | +3.5% | +4.9% | −22.0% | −3.8% | +8.2% | −3.8% | +3.1% | +30.6% | +20.5% | +1.6% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 1.1% | −5.3% | −5.0% | 6.5% | 8.7% | 28.2% | 45.3% | 73.4% | −419.8% | −71.9% |
| Return on invested capital (ROIC) | 5.4% | −1.7% | −10.3% | 5.2% | 8.8% | 60.4% | 63.7% | 93.6% | 46.5% | −28.9% |
| Return on assets (ROA) | 0.6% | −2.7% | −2.4% | 3.1% | 4.0% | 12.6% | 17.2% | 13.8% | −55.0% | −18.8% |
| Return on tangible assets | 1.2% | −3.4% | −2.7% | 3.9% | 4.5% | 14.0% | 23.0% | 18.5% | −69.6% | −25.0% |
| Free cash flow margin | 14.3% | −0.9% | −7.6% | 10.0% | 10.6% | 32.2% | 25.7% | 27.2% | 35.9% | −72.6% |
| Income quality (OCF / net income) | 19.19 | — | — | 1.64 | 2.37 | 2.22 | 1.83 | 1.62 | — | — |
| Financial health | ||||||||||
| Total debt | $115.8M | $116.3M | $171.5M | $166.7M | $183.4M | $132.6M | $58.2M | $83.4M | $82.2M | $67.4M |
| Cash & short-term investments | $179.8M | $173.9M | $213.4M | $207.3M | $217.6M | $167.9M | $74.3M | $80.3M | $70.4M | $33.5M |
| Net debt | −$64.0M | −$57.6M | −$41.9M | −$40.6M | −$34.2M | −$35.4M | −$16.1M | $3.1M | $11.8M | $33.9M |
| Debt / equity | 0.42 | 0.51 | 0.78 | 0.81 | 0.84 | 0.88 | 0.50 | 1.35 | 5.10 | 2.45 |
| Debt / assets | 0.23 | 0.28 | 0.37 | 0.39 | 0.41 | 0.39 | 0.23 | 0.39 | 0.41 | 0.51 |
| Net debt / EBITDA | −1.84 | −3.53 | −4.24 | −1.21 | −0.70 | −0.61 | −0.23 | 0.13 | — | — |
| Current ratio | 2.59 | 3.77 | 4.06 | 4.65 | 5.33 | 3.43 | 1.05 | 1.40 | 1.51 | 1.21 |
| Quick ratio | 2.03 | 3.02 | 3.33 | 3.94 | 4.75 | 3.15 | 0.90 | 1.19 | 1.19 | 0.86 |
| Interest coverage | 1.9 | -0.4 | -3.7 | 1.8 | 2.7 | 7.4 | 5.1 | 2.7 | 0.6 | -1.9 |
| Working capital | $183.6M | $211.9M | $238.4M | $217.8M | $229.8M | $152.6M | $5.2M | $32.8M | $35.7M | $11.4M |
| Invested capital | $213.0M | $171.4M | $176.9M | $164.0M | $184.5M | $114.8M | $101.2M | $64.9M | $28.0M | $61.3M |
| Tangible asset value | $9.3M | $165.7M | $147.5M | $129.5M | $123.8M | $77.6M | $38.0M | $1.8M | −$45.4M | −$30.7M |
| Net current asset value | $76.6M | $103.0M | $72.3M | $56.3M | $51.1M | $23.1M | −$19.1M | −$37.3M | −$70.9M | −$39.0M |
| Graham number | $1.87 | — | — | $2.98 | $3.20 | $4.41 | $3.89 | $2.44 | — | — |
| Graham net-net per share | $0.43 | $0.82 | $0.45 | $0.31 | $0.28 | −$0.02 | −$0.41 | −$0.64 | −$1.42 | −$1.09 |
| Capital allocation | ||||||||||
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 | — |
| Dividend payout ratio | 0.0% | — | — | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Dividends + buybacks / free cash flow | 0.0% | — | — | 0.0% | 0.0% | 0.0% | 0.0% | — | 0.0% | — |
| Capex / revenue | 0.2% | 0.3% | 0.6% | 1.0% | 8.4% | 7.2% | 13.4% | 2.8% | 6.7% | 9.5% |
| Capex / operating cash flow | 1.4% | — | — | 8.8% | 44.2% | 18.3% | 34.3% | 9.3% | 15.8% | — |
| Capex / depreciation | 0.07 | 0.05 | 0.09 | 0.15 | 0.85 | 1.84 | 4.39 | 0.57 | 1.77 | 2.00 |
| Stock-based compensation / revenue | 3.7% | 3.8% | 3.8% | 3.1% | 4.6% | 3.1% | 2.3% | — | — | — |
| R&D / revenue | 26.7% | 28.0% | 28.1% | 25.5% | 35.4% | 18.2% | 16.8% | 21.4% | 20.8% | 96.9% |
| SG&A / revenue | 31.2% | 33.4% | 35.7% | 33.5% | 27.4% | 30.6% | 29.5% | 30.3% | 41.7% | 48.4% |
| Efficiency | ||||||||||
| Days sales outstanding | 51.7 | 58.1 | 50.5 | 50.2 | 46.4 | 41.4 | 42.6 | 28.6 | 25.8 | 91.7 |
| Days of inventory on hand | 491.7 | 590.1 | 717.2 | 761.6 | 416.8 | 260.1 | 255.8 | 282.8 | 499.5 | 1,356.6 |
| Days payables outstanding | 466.6 | 136.5 | 179.3 | 180.5 | 169.6 | 400.6 | 368.0 | 136.0 | 210.9 | 261.4 |
| Cash conversion cycle (days) | 76.8 | 511.6 | 588.5 | 631.3 | 293.6 | -99.2 | -69.6 | 175.3 | 314.3 | 1,186.9 |
| Receivables turnover | 7.05 | 6.29 | 7.22 | 7.26 | 7.87 | 8.82 | 8.57 | 12.76 | 14.17 | 3.98 |
| Payables turnover | 0.78 | 2.67 | 2.04 | 2.02 | 2.15 | 0.91 | 0.99 | 2.68 | 1.73 | 1.40 |
| Inventory turnover | 0.74 | 0.62 | 0.51 | 0.48 | 0.88 | 1.40 | 1.43 | 1.29 | 0.73 | 0.27 |
| Asset turnover | 0.82 | 0.68 | 0.55 | 0.47 | 0.50 | 0.71 | 0.81 | 0.75 | 0.65 | 0.17 |
| Average receivables | $53.3M | $47.3M | $34.0M | $28.3M | $25.3M | $24.1M | $22.1M | $12.1M | $7.6M | $4.2M |
| Average payables | $58.2M | $13.2M | $12.4M | $8.7M | $9.8M | $25.8M | $24.1M | $9.5M | $8.6M | $3.5M |
| Average inventory | $61.3M | $57.2M | $49.5M | $36.6M | $24.1M | $16.8M | $16.8M | $19.7M | $20.4M | $18.3M |
| Intangibles / total assets | 53.6% | 15.3% | 15.4% | 17.6% | 21.1% | 21.2% | 31.0% | 28.0% | 34.1% | 44.7% |
Computed from PHAR's annual financial statements (latest annual report filed April 2, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PHAR valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Pharming traded at 442.0 times earnings, against a 10-year median of 58.5. Based on the latest twelve months, the trailing P/E is 72.0 and the forward P/E is 212.8. Pharming earned a return on equity of 1.1% and a return on invested capital of 5.4% in fiscal 2025. It ended the year with $115.8 million of debt and $179.8 million in cash and short-term investments, a net cash position of $64.0 million. The share count rose 37.4% from 51.9M to 71.3M over 9 years.
See the PHAR income statement, the PHAR chart for price history, or the PHAR stock overview for the latest quote and news.
PHAR key metrics FAQ
What is Pharming's P/E ratio?
Pharming's trailing P/E ratio is 72.0 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 212.8. At the end of fiscal 2025 it was 442.0, compared with a 10-year median of 58.5.
What is Pharming's EV/EBITDA?
Pharming's enterprise value was 34.4 times EBITDA at the end of fiscal 2025 (enterprise value $1.2 billion, EBITDA $34.8 million); the current EV/EBITDA is 19.0.
What is Pharming's return on equity?
Pharming's return on equity (ROE) was 1.1% in fiscal 2025: net income of $2.9 million on average shareholders' equity of $253.0 million.
What is Pharming's ROIC?
Pharming's return on invested capital was 5.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Pharming have?
Pharming had total debt of $115.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.42 and more cash than debt.
Does Pharming pay a dividend?
Pharming did not pay a dividend in fiscal 2025.
What is Pharming's free cash flow yield?
Pharming generated $54.0 million of free cash flow in fiscal 2025, a free cash flow yield of 4.3% on its market value at year-end ($1.3 billion).
What is Pharming's current ratio?
Pharming's current ratio was 2.59 at the end of fiscal 2025: current assets were 2.59 times current liabilities.